Background/aims: To determine whether the use of narrow-band imaging (NBI) system could enhance the detection rate of esophageal squamous cell carcinoma and precancerous lesions during endoscopic examination of the esophagus.
Methodology: 113 patients were randomized to undergo endoscopic examination using high definition television (HDTV) narrow band imaging (NBI) endoscopy or HDTV WL endoscopy. The primary endpoint was the difference in the neoplasm miss rate, and secondary outcome was the neoplasm detection rate.
Results: The number of esophageal cancer and high grade intraepithelial neoplasia lesions detected by HD-NBI and HD-WL was 45 and 21, respectively. The neoplasm miss rate per lesion and per patient with HD-NBI showed significant difference compared with that of HD-WL (P <0.05). Characteristics of lesions missed by use of HD-NBI were similar to those missed by use of HD-WL; all missed lesions were high grade intraepithelial neoplasia lesions. Significant difference was observed between NBI and WL in adenoma detection rate (70.2% vs. 35.7%, P < 0.01).
Conclusions: Endoscopy with HD-NBI seems to improve the detection of esophageal cancer and precancerous lesions, high definition may be tested for its effect on detection of esophageal cancer and precancerous lesions in the future. These results indicate that endoscopy routinely using the NBI system for the surveillance of esophageal cancer and precancerous lesions may be recommended.
Download full-text PDF |
Source |
---|
Esophagus
January 2025
Department of Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980-8574, Japan.
Background: Neoadjuvant chemotherapy is standard for advanced esophageal squamous cell carcinoma, though often ineffective. Therefore, predicting the response to chemotherapy before treatment is desirable. However, there is currently no established method for predicting response to neoadjuvant chemotherapy.
View Article and Find Full Text PDFHealth Econ Rev
January 2025
Department of Pharmacy, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.
Background: The ORIENT-15 double-blind randomized controlled trial demonstrated that the addition of sintilimab to chemotherapy for locally advanced or metastatic oesophageal squamous cell carcinoma (OSCC) resulted in better clinical outcomes. In this analysis, we sought to evaluate the cost-effectiveness of sintilimab as a first-line treatment for locally advanced or metastatic OSCC from a healthcare system perspective in China.
Methods: A partitioned survival model was constructed to perform a cost-effectiveness analysis comparing chemotherapy alone with sintilimab for locally advanced or metastatic OSCC patients.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Esophageal carcinoma is a highly prevalent malignancy worldwide. The present study aimed to investigate the mechanism by which the natural compound coptisine affects pyroptosis in esophageal squamous cell carcinoma (ESCC). The expression of c-Met in ESCC patients was assessed by immunohistochemical analysis of tissue microarrays.
View Article and Find Full Text PDFJ Cancer Prev
December 2024
Department of Animal Science and Biotechnology, Research Institute for Innovative Animal Science, Kyungpook National University, Sangju, Korea.
Esophageal squamous cell carcinoma (ESCC) is among the most prevalent forms of esophageal cancer globally, with a particularly high incidence in developing countries. Notably, Asia accounts for approximately 80% of global esophageal cancer cases, with China alone contributing to 54% of this burden. The primary treatment modality for ESCC remains esophagectomy, primarily employed for locally advanced disease, often in combination with chemotherapy and radiotherapy for advanced-stage cases.
View Article and Find Full Text PDFBr J Dermatol
January 2025
Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA.
Recessive dystrophic epidermolysis bullosa (RDEB) is a genetic disorder due to pathogenic variants in the COL7A1 gene. In this study we determined the association between different categories of COL7A1 variants and clinical disease severity in 236 RDEB patients in North America. Published reports or in-silico predictions were used to assess the impact of pathogenic variants in COL7A1 on type VII collagen (C7) protein function.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!